Christopher J Sweeney

Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model

Liang Cheng, Gary D Hutchins, Qi-Huang Zheng, 2006, The Prostate.

Impact of age at diagnosis of de novo metastatic prostate cancer on survival

Jennifer R. Rider, S. Sridhar, C. Sweeney, 2019, Cancer.

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

David S Mendelson, M. Morris, H. Scher, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

David F Jarrard, Yu-Ning Wong, Nicholas J Vogelzang, 2015, The New England journal of medicine.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

David F Jarrard, Nicholas J Vogelzang, C. Kyriakopoulos, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco‐associated cancers, lung and bladder cancer, by targeting NF‐κB and generating reactive oxygen species

Peter Crooks, Liang Cheng, Harikrishna Nakshatri, 2011, International journal of cancer.

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Thomas Yu, Tapio Pahikkala, Antti Airola, 2017, The Lancet. Oncology.